Skip to content
  • Tuesday, 27 October 2026
  • 4:29 pm
  • Follow Us
Lab DB
  • Home
  • About Us
    • About Us
    • Affiliate Disclosure
    • Cookie Policy
    • Disclaimer
    • Privacy Policy
    • DMCA
    • Terms of Service
  • Contact Us
  • FAQ
  • Home
  • Novo Nordisk Expands Cardiometabolic Portfolio With $2.3bn Hengrui Licensing Deal for Once-Weekly Oral GLP-1/GIP Agonist HRS-1596
Pharmaceutical R&D

Novo Nordisk Expands Cardiometabolic Portfolio With $2.3bn Hengrui Licensing Deal for Once-Weekly Oral GLP-1/GIP Agonist HRS-1596

Teuku Ryan Sep 29, 2026 0

In a strategic move to cement its leadership in the booming cardiometabolic therapeutics market, Danish pharmaceutical titan Novo Nordisk has…

Read More
Pharmaceutical R&D

Bristol Myers Squibb and Hengrui Pharma Forge Landmark $15.2 Billion Oncology and Immunology Collaboration

Teuku Ryan May 13, 2026 0

Bristol Myers Squibb (BMS) and Chinese biopharmaceutical giant Hengrui Pharma have announced a monumental licensing and collaboration agreement, potentially valued…

Read More
Science News: A Century of Empowering Public Understanding of ScienceBreaking the Physical Ceiling of Solar Energy Researchers Achieve 130 Percent Efficiency Through Singlet Fission and Molybdenum Spin Flip EmittersCanada’s Drug Agency Data Reveals Evolving Landscape of Drug Approvals and ReimbursementThe Jovian System’s Icy Moons May Have Received the Building Blocks of Life from Their Nascent Environment
The Most Favored Nation (MFN) Policy’s Unforeseen Ripple Effect: European Pharmaceutical Launches and Withdrawals PlummetJapan’s FY26 NHI Drug Price Revision: Deeper Dive into Mechanisms and Market ImpactEliquis Loss of Exclusivity: A Pharmaceutical Patent Cliff of Historic ProportionsMEDVi Under Scrutiny: AI-Powered Telehealth Startup Faces FDA Warnings, Deceptive Marketing Allegations, and Multiple Lawsuits Despite Meteoric Growth
Merck and Moderna’s cancer vaccine is customized for each patient’s tumorAn Unbiased Look at Google Gemini Omni: Features, Costs, and Market ComparisonESMO 2026: Sacituzumab Tirumotecan Sets New Survival Benchmark in Recurrent Endometrial CancerLight-Driven Magnetism Breakthrough Promises Ultrafast, High-Density Digital Data Storage
YOU MAY HAVE MISSED
Laboratory Automation & Robotics
Merck and Moderna’s cancer vaccine is customized for each patient’s tumor
Lana Keisha Oct 27, 2026
Data Science & Bioinformatics
An Unbiased Look at Google Gemini Omni: Features, Costs, and Market Comparison
Evan Lee Salim Oct 27, 2026
Pharmaceutical R&D
ESMO 2026: Sacituzumab Tirumotecan Sets New Survival Benchmark in Recurrent Endometrial Cancer
Teuku Ryan Oct 27, 2026
Advanced Materials Science
Light-Driven Magnetism Breakthrough Promises Ultrafast, High-Density Digital Data Storage
Nila Kartika Wati Oct 27, 2026

Copyright © 2026 | Powered by WordPress | News Gadgets by ThemeArile

  • Home
  • About Us
    • About Us
    • Affiliate Disclosure
    • Cookie Policy
    • Disclaimer
    • Privacy Policy
    • DMCA
    • Terms of Service
  • Contact Us
  • FAQ